Biaya Penggunaan Obat Hipoglikemik Oral (Oho) Metformin Dan Glimepirid Pada Pasien Diabetes Melitus Tipe Ii Rawat Jalan Non BPJS Di Serang Tahun 2018 Tidak Berbeda Signifikan

Abstract

Diabetes mellitus (DM) is one of the four priorities of non-infectious diseases in the world, divided into type I DM and type II DM. This research was conducted to non-government insurance patients, in order to see the difference in the cost of using Oral Hypoglycemic Drugs (OHDs), namely Metformin and Glimepiride in Serang, because there is hig incidence of type II DM there. There were more than 500 outpatients in 2018, with around 70-100 non-government insurance patients. This study was an observational analytic study using a crosssectional approach whose data were taken retrospectively. Subjects were nongovernment insurance type II DM outpatients in 2018, aged 20-65 years, and adhering to treatment using Metformin and Glimepiride. The tools used are paper,

Narrative Review: Cost-Effectiveness Analysis of the Use of Oral Antidiabetic Drugs Biguanide and Sulfonylurea Group in Patients With Type 2 Diabetes Mellitus

“…Research at Sitnala Hospital by Laelasari et al ( 2017) is an analytical descriptive study with a cross-sectional research design that tested the effectiveness and cost difference in type 2 Diabetes Mellitus patients followed by 97 patients selected using purposive sampling techniques 11 12 A Research conducted by Romadhoni (2018), a descriptive retrospective previously, with a sample of 28 patients taken purposive sampling, the sample was divided into two groups that received metformin therapy as many as 20 Glimepiride as eight patients. 12 Analysis conducted in this study calculated Average Cost-Effectiveness ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER) by looking at changes in outcomes and achieving GDS targets. The group that got glimepiride was the most costeffective option than the metformin group with a total cost of Rp 432,221 and 62.5% effectiveness, followed by Metformin for Rp 498,627.80 and 70% effectiveness.…”

“…In previous studies, patients suffering from hypertension used amlodipine drugs from the CCB group to regulate hypertension, which has particular indications for patients at high risk of coronary disease and diabetes. 12 On the Dhakal et al study. (2019) 58.7% of patients have comorbid disease, hypertension has 45.3% of the total patient sample.…”

“…However, between the two, there was no significant difference in the average cost of the drug. 12 Analysis economics is performed by Nian et al (2020) against dapagliflozin and metformin, an analytical method using the Chinese Outcomes Model for T2DM. These drugs were tested with a placebo to see their ability to lower blood sugar levels.…”